On November 21, 2023, Immix Biopharma, Inc. achieved a major milestone as the FDA granted clearance for their Investigational New Drug (IND) application for BCMA CAR-T NXC-201. This exciting development allows for the expansion of studies on NXC-201 in relapsed/refractory AL Amyloidosis to the United States. Notably, this marks the first CAR-T program specifically designed for light-chain (AL) Amyloidosis. The favorable tolerability of NXC-201 also presents the potential for its use in autoimmune indications, further highlighting its versatility.
Dr. Ilya Rachman, CEO of Immix Biopharma, expressed his enthusiasm about the FDA clearance, revealing that multiple leading U.S. medical facilities are preparing to enroll patients in the upcoming months. This news is particularly significant as there are currently no approved treatment options available for relapsed/refractory AL Amyloidosis patients, making NXC-201 a much-needed breakthrough in the field.
During the 65th American Society of Hematology (ASH) Annual Meeting and the IMS 20th Annual Meeting, the NXC-201 clinical data was presented. The findings demonstrated the feasibility and favorable tolerability of NXC-201 in patients with relapsed/refractory AL Amyloidosis. Remarkably, the data showcased that NXC-201 not only exhibited safety but also elicited hematologic and organ responses in these patients, including those who were considered frail. However, it is important to note that deaths due to cardiac disease within the first year of treatment were observed.
Recognizing its potential, the FDA has granted NXC-201 orphan drug designations as a potential therapeutic option for patients with multiple myeloma and AL amyloidosis. The manufacturing process for NXC-201 has been reported to take approximately 10 days, and patients undergo lymphodepletion before receiving the infusion of this CAR T-cell therapy.
In conclusion, the FDA’s approval of the IND application for NXC-201 is a significant breakthrough in the realm of CAR-T therapy, particularly for the treatment of relapsed/refractory AL Amyloidosis. The favorable tolerability and the possibility of expanding into autoimmune indications make NXC-201 an incredibly promising candidate for addressing the unmet medical needs of these patient populations.
Immix Biopharma, Inc.
Updated on: 29/11/2023
Debt to equity ratio: Neutral
Price to earnings ratio: Neutral
Price to book ratio: Neutral
DCF: Strong Buy
ROE: Strong Sell
4:00 AM (UTC)
Date:29 November, 2023
There are no analysts data to display
IMMX Stock Performance on November 21, 2023: Mixed Results and Limited Insights for Investors
IMMX stock had a mixed performance on November 21, 2023. The stock opened at $4.48, slightly higher than the previous day’s close of $4.39. Throughout the day, the stock’s price fluctuated within a range of $4.05 to $4.78. The trading volume for the day was 11,726 shares, which is significantly lower than the average volume of 184,029 shares over the past three months.
IMMX, a company in the Health Technology sector and the Pharmaceuticals: Major industry, has shown strong earnings growth in the past year, with a growth rate of 66.25%. However, there is no information available regarding its earnings growth for the current year or the next five years. Similarly, there is no data provided on the revenue growth for the previous year or the price/sales and price/book ratios.
The next reporting date for IMMX is November 29, 2023, when the company is expected to release its financial results for the quarter. The EPS forecast for this quarter is -$0.16, indicating a projected loss. The annual revenue for the previous year was $0.00, and the company reported a net loss of -$8.2 million.
In conclusion, based on the limited information available, IMMX stock had a mixed performance on November 21, 2023. While the stock’s price opened slightly higher than the previous day’s close, it experienced fluctuations throughout the day. The company has shown strong earnings growth in the past year but lacks data on its current and future earnings growth, as well as revenue growth. Investors will have to wait for the next reporting date to gain more insights into the company’s financial performance.
Immix Biopharma Inc: Promising Future Prospects and Analyst Consensus to Buy Stock
Immix Biopharma Inc, a biopharmaceutical company, has been attracting attention from investors due to its promising future prospects. According to the data provided by CNN Money, the one analyst offering a 12-month price forecast for IMMX stock has a median target of $14.00, with a high estimate of $14.00 and a low estimate of $14.00. This median estimate represents a significant increase of 225.58% from the last price of $4.30.
The consensus among investment analysts is to buy stock in Immix Biopharma Inc. This rating has remained steady since October, when it was unchanged from a buy rating. This indicates that investors have confidence in the company’s performance and believe that it has the potential for growth in the coming months.
It is essential to consider the financial performance of Immix Biopharma Inc to understand the factors contributing to the positive outlook. As of the current quarter, the company reported an earnings per share of -$0.16 and sales of $0.00. These figures suggest that the company is still in its early stages and may not have generated significant revenue yet. However, it is important to note that the reporting date for the current quarter is November 29, which means that the latest financial information is not yet available.
Investors should keep an eye on Immix Biopharma Inc and closely monitor its financial performance in the upcoming quarters. The positive outlook from analysts and the consensus to buy the stock indicate that there is potential for significant growth. However, it is essential to conduct thorough research and consider other factors before making any investment decisions.
As with any investment, it is important to note that stock prices are subject to market fluctuations and can be influenced by various factors. Investors should exercise caution and consult with a financial advisor before making any investment decisions.